Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:

NCT ID: NCT02317861 Completed - Clinical trials for Gout and Asymptomatic Hyperuricemia

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore the pharmacodynamics (PD), pharmacokinetics (PK), safety, and tolerability of multiple doses of RDEA3170 administered in combination with febuxostat compared to RDEA3170 administered alone and febuxostat administered alone in Japanese adult male subjects with gout or asymptomatic hyperuricemia.

NCT ID: NCT02290210 Completed - Gout Clinical Trials

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

Start date: July 24, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

NCT ID: NCT02287818 Completed - Gout Clinical Trials

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Start date: December 2014
Phase: Phase 2
Study type: Interventional

The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of gout flares during ULT.

NCT ID: NCT02279641 Completed - Gout Clinical Trials

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Start date: November 1, 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.

NCT ID: NCT02252835 Completed - Gout Clinical Trials

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.

NCT ID: NCT02246673 Completed - Gout Clinical Trials

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Start date: October 2014
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.

NCT ID: NCT02219516 Completed - Gout Clinical Trials

Mild, Moderate and Severe Renal Impairment Study

Start date: August 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.

NCT ID: NCT02139046 Completed - Gout Clinical Trials

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

Start date: May 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.

NCT ID: NCT02128490 Completed - Gout Clinical Trials

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment.

NCT ID: NCT02113111 Completed - Clinical trials for Cardiovascular Diseases

Effects of Fasting on Self Efficacy

TheraFast
Start date: April 2014
Phase: N/A
Study type: Observational

The study aims to investigate - if a 7 day therapeutic fasting regimen will affect self-efficacy of patients with chronic diseases - the effects of fasting on physical and mental well-being, quality of life and body awareness/image - the association between patients characteristics and the perceived health benefit after fasting - the association between Diagnosis according to traditional Chinese medicine and physical and mental well-being during the course of fasting - experiences and perceptions of patients during fasting therapy